Integrating the pre-clinical pharmacokinetic, pharmacodynamics, and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm plus ) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients.

被引：3

作者：

Ballard, Peter ^{[1
]}

Ashton, Susan ^{[1
]}

Cross, Darren ^{[1
]}

Dimelow, Richard ^{[2
]}

Yates, James ^{[1
]}

机构：

[1] AstraZeneca, Macclesfield, Cheshire, England

[2] Wright Dose, Altrincham, Cheshire, England

来源：

关键词：

D O I：

10.1158/1535-7163.TARG-13-13212

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

B212

引用

页数：1